Maryland partnership expands Trulieve’s product mix

Dabstract’s decision to launch its High Terpene Extract products in Maryland through a partnership with Trulieve Cannabis (CNSX:TRUL) gives Trulieve access to award-winning live resin vape formats across adult-use and medical channels.

The collaboration pairs Dabstract’s proprietary extraction and strain specific formulations with Trulieve’s existing Maryland footprint. This may broaden the retailer’s premium concentrate offering at select dispensaries, with room for additional formats over time.

See our latest analysis for Trulieve Cannabis.

Trulieve’s latest product partnership lands at a time when the share price, now at CA$8.48, shows strong short-term momentum, with a 7 day share price return of 16.16% but a 90 day share price return decline of 28.80%, while the 1 year total shareholder return of 86.37% sits against a 5 year total shareholder return decline of 83.43%.

If this kind of product expansion catches your eye, it can be worth widening your watchlist to see which other cannabis and wellness names are moving, starting with 2 top founder-led companies

With Trulieve trading at CA$8.48 and an intrinsic value estimate more than double that, along with mixed short and long term returns, is the market offering a discount or already pricing in future growth?

Most Popular Narrative: 56.6% Undervalued

Trulieve’s most followed valuation narrative places fair value at CA$19.53 versus the current CA$8.48 share price, framing a large gap that hinges on regulatory change and margin recovery.

Pending federal policy changes specifically cannabis rescheduling to Schedule III and progress on SAFER Banking legislation are expected to substantially lower Trulieve’s tax burden (eliminating the punitive 280E provision) and unlock improved access to financing, which would directly increase net margins and cash flow.

Read the complete narrative.

Want to see what kind of revenue runway, margin shift, and future earnings multiple have to line up to support that valuation gap? The narrative leans on a specific growth pace, a meaningful swing in profitability, and a premium earnings multiple that together have to coexist for CA$19.53 to hold up.

Result: Fair Value of CA$19.53 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, this depends on Florida concentration and ongoing losses, where pricing pressure, regulatory setbacks, or funding challenges could quickly weaken the undervaluation case.

Find out about the key risks to this Trulieve Cannabis narrative.

Next Steps

With mixed signals across valuation, regulation, and profitability, sentiment on Trulieve is understandably split. It makes sense to move quickly and test the data for yourself using the 1 key reward and 1 important warning sign.

Looking for more investment ideas?

If Trulieve is on your radar, do not stop there. Broaden your opportunity set with a few focused stock ideas that match different goals and risk levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com